ライフサイエンスコーパス: blebbistatin

1 ed by treatment with the myosin II inhibitor blebbistatin.

2 on, but failing to move into lamellipodia in blebbistatin.

3 till present when active force is blocked by Blebbistatin.

4 d in cells treated with the motor inhibitor, blebbistatin.

5 with ML7 and myosin II ATPase activity with blebbistatin.

6 was blocked by inhibition of myosin II with blebbistatin.

7 ly 90% at 40 microM actin in the presence of blebbistatin.

8 P(i) release was blocked in the presence of blebbistatin.

9 stabilized by either lattice compression or blebbistatin.

10 acted collagen fibrils, which was blocked by blebbistatin.

11 cle types and in the presence and absence of blebbistatin.

12 activation and were abolished or reversed by blebbistatin.

13 he inhibition of myosin ATPase activity with blebbistatin.

14 the actomyosin inhibitors cytochalasin D and blebbistatin.

15 low myosin affinity and water solubility of blebbistatin.

16 identical inhibitory properties to those of blebbistatin.

17 rdered lipids, was also reduced by Lat B and blebbistatin.

18 +/- 15 years) using the dye Di-4-ANBDQBS and blebbistatin.

19 NM II or treatment with the myosin inhibitor blebbistatin.

20 interference (RNAi) and the myosin inhibitor blebbistatin.

21 ay were not significantly altered by binding blebbistatin.

22 d after injection of the myosin II inhibitor blebbistatin.

23 lowing inhibition of myosin II function with blebbistatin.

24 d by myofilament Ca(2+) desensitization with blebbistatin.

25 ted by myofilament Ca2+ desensitization with blebbistatin.

26 -1)) was reduced slightly in the presence of blebbistatin (0.38 +/- 0.03 microM(-1) s(-1)), while man

27 (3 to 30 micromol/L) and myosin II inhibitor blebbistatin (1 to 10 micromol/L) inhibited CyPA secreti

28 The negative inotropic agents BDM (5 mm) or blebbistatin (10 microM) decreased cell shortening and N

29 esis when myosin contractility is blocked by blebbistatin [4].

30 These properties make blebbistatin a useful tool in structural and functional

31 ma invasion we blocked glioma migration with blebbistatin, a blocker of myosin kinase II, which is ne

32 Blebbistatin, a cell-permeable inhibitor of class-II myo

33 ated in porcine TM and CB cells treated with blebbistatin, a cell-permeable, specific inhibitor of my

34 scle myosin-2 is uniquely insensitive toward blebbistatin, a commonly used myosin-2 inhibitor.

35 We observed that blebbistatin, a myosin II inhibitor, completely and reve

36 tility-previously assumed-was verified using blebbistatin, a myosin-II ATPase inhibitor that permitte

37 dividing normal rat kidney (NRK) cells with blebbistatin, a potent inhibitor of the nonmuscle myosin

38 Pulse-chase studies revealed that Blebbistatin, a specific myosin II inhibitor, severely i

39 Consistent with this, embryos treated with Blebbistatin-a small molecule inhibitor for myosin II ac

40 Blebbistatin also inhibits cell streaming and plaque exp

41 rements of single ATP turnovers to show that blebbistatin also stabilizes the SRX in both fast and sl

42 n and disassembly of the AJC were blocked by blebbistatin, an inhibitor of nonmuscle myosin II.

43 to a virion surface protein and by the drugs blebbistatin and bafilomycin A1, suggesting that in each

44 Using blebbistatin and other drugs, we showed that exit from t

45 ity, while the nonmuscle myosin II inhibitor blebbistatin and the kinesin inhibitor AMP-PNP had no si

46 sforming growth factor-beta, a decrease with blebbistatin, and no change with mechanosensitive channe

47 ulin B (Lat B), inhibition of myosin II with blebbistatin, and treatment with neomycin to sequester p

48 hereas the macropinocytosis inhibitors EIPA, blebbistatin, and wortmannin and the caveolin-mediated e

49 The spectra for skeletal muscle with blebbistatin are similar to those observed in relaxed ta

50 , butanedione monoxime, trifluoperazine, and blebbistatin) are modified by twitchin phosphorylation a

51 tion, as exposure to the myosin-II inhibitor blebbistatin arrested any shortening and also decreased

52 Pretreatment with Y-27632 and blebbistatin (as inhibitors of actomyosin contraction) r

53 Blebbistatin at > or = 30 microM inhibited anterior redi

54 Local release of blebbistatin at the equator caused localized accumulatio

55 signals inasmuch as treatment with Y27632 or blebbistatin attenuated 488-FN assembly.

56 contraction with the myosin ATPase inhibitor blebbistatin attenuated oxidative stress as well as spon

57 lar simulations indicate that the productive blebbistatin-binding site of the myosin head is within t

58 A single intra-BLC treatment with Blebbistatin (Blebb), a small-molecule inhibitor of clas

59 e cytoskeleton inhibitors cytochalasin B and blebbistatin blocked not only PMA-induced apoptosis but

60 trations of the specific myosin II inhibitor blebbistatin blocked PDGF-stimulated matrix contraction

61 The property that blebbistatin blocks myosin II in an actin-detached state

62 2-E1 and myo2-E1-Sup1 on available rigor and blebbistatin-bound myosin II structures suggests that my

63 mall molecules - omecamtiv mecarbil (OM) and blebbistatin (BS) - that bind specifically to myosin and

64 ly Dictyostelium myosin that is inhibited by blebbistatin but also show that blebbistatin-inactivated

65 Blebbistatin caused a strong inhibition of cytokinesis b

66 edistribution of myosin IIA, with 100 microM blebbistatin causing posterior accumulation.

67 inhibition of myosin-II ATPase with the drug blebbistatin decreased cell spreading with associated nu

68 Blebbistatin decreased fibricarrier number and increased

69 r, inhibiting the motor protein myosin II by blebbistatin decreased membrane tension, as well as fusi

70 decreasing contractile level with 10 microM blebbistatin decreased stiffness, whereas increasing con

71 ion by 5% dextran T500 or addition of 25 muM blebbistatin decreased the transition temperature to app

72 n relaxed tarantula fibers in the absence of blebbistatin, demonstrating that the structure of the SR

73 e myosin-2 active-site loop switch-2 acts as blebbistatin desensitizer.

74 Blebbistatin did not affect ATP binding and hydrolysis.

75 Blebbistatin did not affect the status of myosin light c

76 Treatment with blebbistatin did not block CR formation but reduced FRAP

77 However, blebbistatin did not improve the order of thick filament

78 In the presence of 100 microM blebbistatin, disordering was at least 10 times slower.

79 actin/myosin machinery with cytochalasin or blebbistatin disrupts polarization of Pk and Stbm, but n

80 in myosin II-null cells, but, unexpectedly, blebbistatin does inhibit macropinocytosis and phagocyto

81 Blebbistatin does not compete with nucleotide binding to

82 ic inhibitor of non-muscle myosin II (NMII), blebbistatin, enhances the survival of hPS cells under c

83 inhibition of both isoforms in culture with blebbistatin enriches for long-term hematopoietic multil

84 We find that the SRX is stabilized using blebbistatin even in conditions that normally destabiliz

85 In the presence of blebbistatin, filament interaction was inhibited.

86 The specific myosin inhibitor blebbistatin fully blocked this transition.

87 ition of strong cross-bridge attachment with blebbistatin had no effect on the length-dependent modul

88 lete inhibition of active force by 25 microM blebbistatin had very little effect on the Ca(2+)-depend

89 The myosin inhibitor blebbistatin has been shown in structural studies to sta

90 Blebbistatin has some photochemical properties that may

91 ts with inhibitors of cytokinesis, including blebbistatin, hesperadin, and nocodazole, and then assay

92 ich requires myosin II, are not inhibited by blebbistatin in myosin II-null cells, but, unexpectedly,

93 primary porcine TM and CB cells treated with blebbistatin in the presence of serum revealed dose (10-

94 inhibited by blebbistatin but also show that blebbistatin-inactivated myosin II inhibits some myosin

95 he ROCK inhibitor Y27632 or myosin inhibitor blebbistatin increased TER in wild-type cells, whereas Z

96 simplest explanation is that the binding of blebbistatin increases the proportion of myosin in the c

97 In addition, blebbistatin inhibited the ability of epithelial cells t

98 Both blebbistatin-inhibited myosin II and catalytically inact

99 Conversely, blebbistatin inhibition of actomyosin contraction result

100 Blebbistatin inhibition of cytokinesis indicates the imp

101 The effects of TNF-alpha were attenuated by blebbistatin inhibition of myosin II-mediated cytoskelet

102 nclusion, based on biochemical studies, that blebbistatin inhibits myosin ATPase and actin interactio

103 ome myosin II-independent processes and that blebbistatin inhibits other activities in the absence of

104 Blebbistatin inhibits the actin-activated MgATPase activ

105 Based on the above data, we surmise that blebbistatin inhibits the ATPase activity of NMIIB S1 pr

106 Consistent with this use, we find that blebbistatin inhibits three myosin II-dependent processe

107 Blebbistatin interferes neither with binding of myosin t

108 Blebbistatin is a recently discovered small molecule inh

109 Blebbistatin is a small molecule inhibitor discovered in

110 Blebbistatin is a small molecule that affects cell blebb

111 Blebbistatin is a small-molecule, high-affinity, noncomp

112 Loss (siRNA) or inhibition (25 mum blebbistatin) of NM II attenuates the internalization of

113 We examined the effect of blebbistatin on the kinetic properties of nonmuscle myos

114 electron microscopy to study the effects of blebbistatin on the organization of the myosin heads on

115 ues were employed to elucidate the effect of blebbistatin on the various steps of the NMIIB S1 cross-

116 Inhibition of myosin II activity with blebbistatin or by using neurons from myosin IIB knockou

117 llogenesis was tested by treating cells with blebbistatin or calyculin A to tonically block or augmen

118 -beta1)) and low pre-stress by treating with blebbistatin or culture on soft gels (0.6 kPa).

119 f nonmuscle myosin II in human NK cells with blebbistatin or ML-9 impaired neither effector-target ce

120 reated with the myosin II-specific inhibitor blebbistatin or myosin II siRNAs exhibited a significant

121 bryos treated with cell movement inhibitors (blebbistatin or RhoK inhibitor), but not cell cycle inhi

122 tor ML-7 or the myosin II-specific inhibitor blebbistatin or selective RNA-mediated repression of myo

123 Chemical inhibition by blebbistatin or small interfering RNA (siRNA)-mediated s

124 tion of the excitation-contraction uncoupler blebbistatin or the mechanosensitive channel blocker gad

125 KEY POINTS: Omecamtiv mecarbil and blebbistatin perturb the regulatory state of the thick f

126 Myofilament Ca(2+) desensitization with blebbistatin prevented focal energy deprivation, transve

127 Although a myosin II inhibitor, blebbistatin, prevents actin-myosin contractility, the m

128 ine eyes for 5 hours with 100 and 200 microM blebbistatin produced a significant increase (P < 0.01,

129 The protective effect of blebbistatin provides what we believe to be the first di

130 The protective effect of blebbistatin provides what we believe to be the first di

131 Blebbistatin reduces contractility by stabilizing the th

132 Myosin II activity inhibition by blebbistatin rescued the ploidy defect of FPD/AML MKs.

133 argin via Ca(2+) reduction or treatment with blebbistatin restored uniform migration and eliminated A

134 Inhibition of contractility with 10 mum blebbistatin resulted in an approximately 3-fold increas

135 he M466I mutation sensitized the protein for blebbistatin, resulting in a half-maximal inhibitory con

136 ion of myosin II activity through the use of blebbistatin results in microtubules that are still dyna

137 blish an important link between switch-2 and blebbistatin sensitivity.

138 l present when active force was blocked with blebbistatin, showing that C1mC2 directly activates the

139 Furthermore ML-7 and blebbistatin significantly decrease (P < 0.02) C. parvum

140 rization, but not if done in the presence of blebbistatin, suggesting an active role for myosin in co

141 The NM myosin cross-bridge cycling inhibitor blebbistatin suppressed adhesome complex assembly and SM

142 radicals may be produced upon irradiation of blebbistatin that could result in cell damage.

143 a specific inhibitor of nonmuscle myosin II, blebbistatin, that inhibited contraction of the cleavage

144 azidoblebbistatin, which is a derivative of blebbistatin, the most widely used myosin inhibitor.

145 Acute application of blebbistatin to inactivate MII in circuits strongly inhi

146 retraction process, as treating thrombi with blebbistatin to inhibit myosin IIa-mediated platelet con

147 it actin retrograde flow in the LP/dSMAC and blebbistatin to selectively inhibit actomyosin II arc co

148 nd focal adhesions, because of either adding blebbistatin to the cells or use of soft coverslips, als

149 Anterior cytoplasm of blebbistatin-treated cells contained disorganized bundle

150 ent followed advancing lamellipodia, whereas blebbistatin-treated cells extended protrusions without

151 s during late cytokinesis, they persisted in blebbistatin-treated cells over an extended period of ti

152 be useful in locally reversing the action of blebbistatin treatment in a cell.

153 In addition, blebbistatin treatment often resulted in cardia bifida a

154 ore, suppression of actomyosin tension using blebbistatin triggered a similar vinculin delocalization

155 orff-perfused rabbit hearts immobilized with blebbistatin using either a confocal microscope or an op

156 rapidly inactivates the inhibitory action of blebbistatin using the in vitro motility of myosin as an

157 When blebbistatin was added to M.ADP thick filaments, helical

158 In this study, blebbistatin was used to stabilize the closed conformati

159 Using blebbistatin we show that spin-labeled nucleotides bound

160 Furthermore, MLP can be inhibited by blebbistatin, which inactivates myosin II activity and r

161 eduction in cortactin content was blocked by blebbistatin, while basal levels were reduced by nocodaz

162 se effects are likely mediated by binding of blebbistatin within the myosin cleft that progressively